Suchergebnisse - "Brøndum, Rasmus Froberg"

PubPharm (44)

1

Socioeconomic Status and Overall Survival Among Patients With Hematological Malignant Neoplasms

enthalten in: JAMA network open | 2024

von Nielsen, L. | Kristensen, D. | Jakobsen, L. | +5

2

A clinical proteomics study of exhaled breath condensate and biomarkers for pulmonary embolism

enthalten in: Journal of breath research | 2023

von Gade, I. | Riddersholm, S. | Stilling-Vinther, T. | +3

3

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy

enthalten in: European journal of haematology | 2023

von Kristensen, D. | Brøndum, R. | Ørskov, A. | +6

4

Venetoclax‐based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy

enthalten in: European Journal of Haematology | 2023

von Kristensen, D. | Brøndum, R. | Ørskov, A. | +6

5

Author Correction : Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction

enthalten in: Scientific reports | 2022

von Knudsen, T. | Brøndum, R. | Stoustrup, J. | +1

ErratumFor: Sci Rep. 2021 Dec 30;11(1):24498. - PMID 34969959

6

Mathematical modelling of SARS-CoV-2 variant outbreaks reveals their probability of extinction

enthalten in: bioRxiv.org | 2022

von Schiøler, H. | Knudsen, T. | Brøndum, R. | +2

7

Implementing a data infrastructure for precision oncology projects leveraging REDCap

enthalten in: bioRxiv.org | 2022

von Vesteghem, C. | Dahl, S. | Brøndum, R. | +15

8

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

9

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

10

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

enthalten in: BMC cancer | 2022

von Schmitz, A. | Brøndum, R. | Johnsen, H. | +24

1
2
3
4
5
Nächster »
[5]